Journal of ethnopharmacology · 2025
Dual COX/5-LOX inhibition by isorhamnetin-3-O-glucoside from Anthyllis cytisoides: An integrated chemical-enzymatic-computational study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bouammali Haytham, Khibech Oussama, Fraj Elmehdi, Elbouzidi Amine, Bekkouch Ayoub, Bourhou Chaymae, Zughaier Susu M, Merzouki Mohammed, Hassiba Maryam, Jaouani Hanane, Bouammali Boufelja, Challioui Allal, Touzani Rachid
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Anthyllis cytisoides L. is a forage shrub native to the western Mediterranean basin, traditionally used in folk medicine to treat respiratory and gastrointestinal inflammation. However, its polar phytochemical profile and the underlying enzyme-level anti-inflammatory mechanisms involving COX-1/COX-2 and 5-LOX remain weakly documented.
AIM OF THE STUDY: To integrate chemical, enzymatic, and computational evidence that links the constituents of A. cytisoides L to COX-1, COX-2, and 5-LOX targets, thereby contextualizing the species' ethnopharmacological indications.
MATERIALS AND METHODS: The aerial parts were subjected to polarity-guided fractionation followed by LC-HRMS profiling. From the methanolic fraction, a flavonol glycoside was isolated and structurally elucidated as isorhamnetin-3-O-glucoside (I3OG) using ESI-MS, IR spectroscopy, and 1D/2D NMR analyses. Enzymatic inhibition of COX-1, COX-2, and 5-LOX was assessed (COX via PGE2 radioimmunoassay; 5-LOX via FOX assay at 560 nm), and IC50 values were calculated using four-parameter logistic regression (95 % CI). Molecular docking (COX-1: 1EQG; COX-2: 5F19; 5-LOX: 6NCF) and 100-ns molecular dynamics simulations (GROMACS) were also performed.
RESULTS: I3OG was successfully identified and purified from A. cytisoides. It inhibited COX-1, COX-2, and 5-LOX with IC50 values of 10.65 ± 1.02, 15.09 ± 0.84, and 15.24 ± 1.18 μg/mL (≈22.3, 31.6, and 31.9 μM), respectively, surpassing the inhibitory activity of the crude extracts for all targets. Docking studies and 100-ns MD simulations confirmed stable interactions with each enzyme, in agreement with the experimental inhibition ranking (COX-1 > COX-2 ≈ 5-LOX).
CONCLUSION: I3OG emerges as a promising dual COX/5-LOX candidate from A. cytisoides, providing a coherent link between detailed phytochemical analysis, enzymatic inhibition, and atomistic binding mechanisms. Although selectivity and safety considerations fall outside the scope of this enzyme-focused study, the findings highlight A. cytisoides as a valuable source of multitarget anti-inflammatory scaffolds and support SAR-driven optimization and formulation strategies aimed at enhancing bioactivity.
AIM OF THE STUDY: To integrate chemical, enzymatic, and computational evidence that links the constituents of A. cytisoides L to COX-1, COX-2, and 5-LOX targets, thereby contextualizing the species' ethnopharmacological indications.
MATERIALS AND METHODS: The aerial parts were subjected to polarity-guided fractionation followed by LC-HRMS profiling. From the methanolic fraction, a flavonol glycoside was isolated and structurally elucidated as isorhamnetin-3-O-glucoside (I3OG) using ESI-MS, IR spectroscopy, and 1D/2D NMR analyses. Enzymatic inhibition of COX-1, COX-2, and 5-LOX was assessed (COX via PGE2 radioimmunoassay; 5-LOX via FOX assay at 560 nm), and IC50 values were calculated using four-parameter logistic regression (95 % CI). Molecular docking (COX-1: 1EQG; COX-2: 5F19; 5-LOX: 6NCF) and 100-ns molecular dynamics simulations (GROMACS) were also performed.
RESULTS: I3OG was successfully identified and purified from A. cytisoides. It inhibited COX-1, COX-2, and 5-LOX with IC50 values of 10.65 ± 1.02, 15.09 ± 0.84, and 15.24 ± 1.18 μg/mL (≈22.3, 31.6, and 31.9 μM), respectively, surpassing the inhibitory activity of the crude extracts for all targets. Docking studies and 100-ns MD simulations confirmed stable interactions with each enzyme, in agreement with the experimental inhibition ranking (COX-1 > COX-2 ≈ 5-LOX).
CONCLUSION: I3OG emerges as a promising dual COX/5-LOX candidate from A. cytisoides, providing a coherent link between detailed phytochemical analysis, enzymatic inhibition, and atomistic binding mechanisms. Although selectivity and safety considerations fall outside the scope of this enzyme-focused study, the findings highlight A. cytisoides as a valuable source of multitarget anti-inflammatory scaffolds and support SAR-driven optimization and formulation strategies aimed at enhancing bioactivity.